MITSUBISHI TANABE PHARMA CORPORATION

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Canagliflozin (TA-7284)
Drug: Placebo
Drug: Insulin

First Posted Date: 2014-08-20

Last Posted Date: 2016-12-15

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 146

Registration Number: NCT02220920

Locations: 🇯🇵
Reserch site, Tohoku, Japan

Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic Nephropathy

Phase 1

Completed

Conditions: Diabetic Nephropathy

Interventions: Drug: Placebo
Drug: MT-3995

First Posted Date: 2014-07-31

Last Posted Date: 2015-09-16

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 31

Registration Number: NCT02205372

Locations: 🇯🇵
Touei Hospital, Sapporo, Hokkaido, Japan

A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303

Phase 1

Completed

Conditions: Relapsing-remitting Multiple Sclerosis

Interventions: Drug: MT-1303-Low
Drug: MT-1303-High
Drug: Placebo
Drug: Fingolimod

First Posted Date: 2014-07-17

Last Posted Date: 2015-02-20

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 81

Registration Number: NCT02193217

Locations: 🇬🇧
Investigational site, Leeds, United Kingdom

Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's Disease

Phase 1

Completed

Conditions: Crohn's Disease

Interventions: Drug: MT-1303

First Posted Date: 2014-05-28

Last Posted Date: 2014-09-12

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 1

Registration Number: NCT02148185

Locations: 🇯🇵
Inverstigational site, Kanto, Japan

Exploratory Clinical Study of MT-2301

Phase 2

Completed

Conditions: Haemophilus Influenza Type b

Interventions: Biological: Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-Low + DPT-IPV
Biological: Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-High + DPT-IPV
Biological: Haemophilus influenza type b conjugate vaccine + DPT-IPV

First Posted Date: 2014-05-16

Last Posted Date: 2015-10-19

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 157

Registration Number: NCT02140047

Locations: 🇯🇵
Investigational site, Fukuoka-shi, Fukuoka, Japan

Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents

Phase 3

Completed

Conditions: Diphtheria
Tetanus
Pertussis

Interventions: Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301)
Biological: Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid)

First Posted Date: 2014-04-21

Last Posted Date: 2017-01-13

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 446

Registration Number: NCT02118961

Locations: 🇯🇵
Investigational site, Shizuoka-shi, Shizuoka, Japan
🇯🇵
Inverstigational site, Shinjuku-ku, Tokyo, Japan

Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Teneli (Teneligliptin)
Drug: Placebo
Drug: Insulin

First Posted Date: 2014-03-07

Last Posted Date: 2017-09-19

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 148

Registration Number: NCT02081599

Locations: 🇯🇵
Investigational site, Chuo-ku, Tokyo, Japan

Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Phase 2

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: MT-1303-Low
Drug: Placebo
Drug: MT-1303-Middle
Drug: MT-1303-High

First Posted Date: 2013-11-19

Last Posted Date: 2014-12-18

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 142

Registration Number: NCT01987843

Locations: 🇺🇦
Research Site, Zaporizhzhya, Ukraine

Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects

Phase 1

Completed

Conditions: Hyperphosphatemia
Chronic Kidney Disease

Interventions: Drug: colestilan
Drug: candesartan

First Posted Date: 2013-11-06

Last Posted Date: 2017-05-12

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 18

Registration Number: NCT01976572

Locations: 🇬🇧
Covance Clinical Research Unit Ltd., Leeds, Springfield House Hyde Street, United Kingdom

A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

Phase 3

Completed

Conditions: Perennial Allergic Rhinitis

Interventions: Drug: Bepotastine besilate

First Posted Date: 2013-07-16

Last Posted Date: 2016-04-08

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 58

Registration Number: NCT01900054

Locations: 🇯🇵
Reserch site, Kanagawa, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy